Discussion Our pooled analysis of seven country-specific RWE studies assessing the use of oral semaglutide in adults with T2D shows that clinically relevant reductions in HbA 1C and body weight are seen regardless of baseline HbA 1C , body weight, age, or T2D duration
Orforglipron vs Farxiga: A New Chapter in Oral Diabetes Therapy Big news from the diabetes frontEli Lillys oral GLP-1 candidate Orforglipron just outperformed Farxiga (dapagliflozin) in two Phase III trials
Glucose transporter 2 (Glut2) and Glucokinase, which respectively mediate two early rate-controlling steps in the glycolytic pathway, glucose uptake and carbon 6 phosphorylation respectively were also investigated
Patients and healthcare providers are encouraged to report suspected adverse effects to the FDA MedWatch program
Klinic prescribes these effective alternatives to aid in your weight loss journey
Millions of people who are enrolled in flexible spending accounts (FSAs) and health savings accounts (HSAs) can now use their tax-free healthcare funds to purchase eligible weight loss services and GLP-1 medications, thanks to a new telehealth collaboration between Health-E Commerce and LifeMD